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Abstract
Salmonella enterica serovar Typhi (S. Typhi) is the causative agent of typhoid fever, a sys-
temic human infection with a burden exceeding 20 million cases each year that occurs dis-
proportionately among children in low and middle income countries. Antimicrobial therapy is
the mainstay for treatment, but resistance to multiple agents is common. Here we report
genotypes and antimicrobial resistance (AMR) determinants detected from routine whole-
genome sequencing (WGS) of 533 S. Typhi isolates referred to Public Health England
between April 2014 and March 2017, 488 (92%) of which had accompanying patient travel
information obtained via an enhanced surveillance questionnaire. The majority of cases
involved S. Typhi 4.3.1 (H58) linked with travel to South Asia (59%). Travel to East and
West Africa were associated with genotypes 4.3.1 and 3.3.1, respectively. Point mutations
in the quinolone resistance determining region (QRDR), associated with reduced suscepti-
bility to fluoroquinolones, were very common (85% of all cases) but the frequency varied sig-
nificantly by region of travel: 95% in South Asia, 43% in East Africa, 27% in West Africa.
QRDR triple mutants, resistant to ciprofloxacin, were restricted to 4.3.1 lineage II and asso-
ciated with travel to India, accounting for 23% of cases reporting travel to the country. Over-
all 24% of isolates were MDR, however the frequency varied significantly by region and
country of travel: 27% in West Africa, 52% in East Africa, 55% in Pakistan, 24% in Bangla-
desh, 3% in India. MDR determinants were plasmid-borne (IncHI1 PST2 plasmids) in S.
Typhi 3.1.1 linked to West Africa, but in all other regions MDR was chromosomally
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integrated in 4.3.1 lineage I. We propose that routine WGS data from travel-associated
cases in industrialised countries could serve as informal sentinel AMR genomic surveillance
data for countries where WGS is not available or routinely performed.
Author summary
Our data demonstrate how routine WGS data produced by Public Health England can be
further mined for informal passive surveillance of Salmonella Typhi circulating in differ-
ent geographical regions where typhoid is endemic. We have shown the public health util-
ity of a simplified approach to WGS reporting based on the GenoTyphi genotyping
framework and nomenclature, which doesn’t require the generation of a phylogenetic tree
or other phylogenetic analysis. These approaches yielded results consistent with previ-
ously reported antimicrobial resistance (AMR) patterns of S. Typhi, including prevalence
of multi-drug resistant (MDR) and fluoroquinolone resistance in different regions in asso-
ciation with different pathogen variants. These data provide a rationale and framework
for the extraction and reporting of geographically stratified genotype and AMR data from
public health labs in non-endemic countries. Prospective analysis and reporting of such
data could potentially detect shifts in regional S. Typhi populations, such as replacement
or spread of different subclades and the emergence and dissemination of MDR, fluoro-
quinolone resistant and/or extensively drug resistant S. Typhi, providing valuable data to
inform typhoid control measures in low and middle income countries that are still build-
ing their genomics capacity.
Introduction
Salmonella enterica serovar Typhi (S. Typhi) is the causative agent of typhoid fever[1], a sys-
temic human infection responsible for an estimated 223,000 deaths each year resulting from
more than 20 million infections[2,3]. The majority of the disease burden falls on children in
low and middle income countries (LMICs)[2], however vaccination programmes are rare in
endemic countries and antimicrobial therapy is considered crucial for the safe clearance of S.
Typhi infections and the avoidance of clinical complications. Historically typhoid fever could
be effectively treated using first-line drugs including chloramphenicol, ampillicin or co-tri-
moxazole. However the emergence of multi-drug resistant (MDR) S. Typhi, defined as display-
ing resistance to all three drugs, in the late 1980s and early 1990s resulted in changes to
treatment guidelines, with fluoroquinolones becoming the recommended therapy[4–7].
Recent years have seen a rise in the proportion of S. Typhi disease isolates displaying reduced
susceptibility to fluoroquinolones associated with point mutations in quinolone resistance
determining region (QRDR) of gyrA and parC[2,8,9].
S. Typhi is genetically monomorphic, which has historically constrained molecular surveil-
lance of S. Typhi before the era of high throughput whole genome sequencing (WGS)[5,10]. A
phylogenetically informative genotyping scheme, GenoTyphi, was recently introduced to facil-
itate the interpretation of S. Typhi WGS data[11]. Application of the scheme to a global collec-
tion of isolates from >60 countries showed that the S. Typhi population is highly structured,
comprising dozens of subclades associated with specific geographical regions[11,12]. This
global genomic framework for S. Typhi revealed the majority of MDR S. Typhi infections
worldwide are associated with a single phylogenetic lineage, designated as genotype 4.3.1 (H58
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under the legacy scheme[5]), which has disseminated from South Asia since the 1990s, includ-
ing into East Africa [11,12]. Contrastingly, in West Africa MDR S. Typhi is associated with a
different genotype, 3.1.1[13,14]. The MDR phenotype in both S. Typhi 4.3.1 and 3.1.1 is
encoded by a composite transposon carrying genes conferring resistance to five drug classes.
These include chloramphenicol, penicillins and co-trimoxazole and the determinants are typi-
cally located on IncH1 plasmids (plasmid sequence type PST6 in 4.3.1, and PST2 in 3.1.1)
[4,12–17]. Recently, migration of the MDR transposon to the S. Typhi chromosome via IS1
transposition has been reported, with four different integration sites identified in the S. Typhi
4.3.1 strain background (fbp, yidA, STY4438 and the intergenic region between cyaA and
cyaY)[12,18–21].
Resistance to newer agents is also on the rise in S. Typhi. Reduced susceptibility to fluoro-
quinolones via QRDR mutations is commonly observed amongst S. Typhi 4.3.1[12], especially
lineage II[16,22], but is rare in 3.1.1 and other genotypes[12,13]. S. Typhi 4.3.1 QRDR triple
mutants (carrying two mutations in gyrA and one in parC) displaying complete resistance to
ciprofloxacin are increasing in prevalence in South Asia[23]. WGS analysis showed that recent
treatment failure with gatifloxacin in Nepal resulted from introduction of a 4.3.1 lineage II tri-
ple mutant from India, prompting a reconsideration of the reliance on fluoroquinolones in the
region[8,22]. Subsequently an outbreak of S. Typhi 4.3.1 displaying resistance to ceftriaxone in
addition to ciprofloxacin and all three first line drugs was reported in Pakistan[24,25]. The
outbreak strain carried both the MDR composite transposon integrated in the chromosome at
yidA, and an E. coli IncY plasmid harbouring the extended spectrum beta-lactamase (ESBL)
gene blaCTX-M-15 (conferring resistance to ceftriaxone and other third generation cephalospo-
rins) and the quinolone resistance gene qnrS (which combined with a gyrA-S83F mutation in
the chromosome conferred resistance to ciprofloxacin)[24]. This strain has been designated
XDR (extensively drug resistant, defined as resistance to chloramphenicol, penicillins, co-tri-
moxazole, ceftriaxone and ciprofloxacin) and severely limits treatment options, with azithro-
mycin being the last remaining oral antibiotic (to which sporadic resistance has already been
observed in South Asia)[7].
These dynamic trends highlight a need for prospective AMR surveillance in global S. Typhi
populations, in order to inform empirical treatment options; genomic surveillance offers the
added benefit of revealing resistance mechanisms and regional and international spread of
emerging MDR and XDR strains[26]. Blood culture confirmation and isolate characterisation
is a pre-requisite for such activities, but neither are routinely performed in laboratories in
areas where typhoid fever is endemic. However, in many developed nations, S. Typhi infec-
tions are notifiable and the disease is primarily associated with travellers returning from high-
risk regions[27], providing an opportunity for informal sentinel surveillance of those regions.
In England, typhoid fever is notifiable and all S. Typhi isolates are sent to Public Health
England (PHE) for confirmation and characterisation via WGS, and recent travel history is
sought via enhanced surveillance questionnaires. Most cases identified in England (~80%) are
associated with recent travel to typhoid endemic areas[27]. We recently reported that the geo-
graphic origin of travel-associated S. Typhi cases in London could be predicted by comparing
WGS data to the global framework[11], and identified the first case of ESBL S. Typhi in
England from a patient with travel to Pakistan[28], supporting the notion that WGS data on
travel-associated cases has sentinel surveillance value. Here we analysed WGS data from S.
Typhi isolates referred to PHE from three years of national surveillance between April 2014
and March 2017[29], and explored the distribution of lineages and AMR determinants in geo-
graphic regions frequented by UK travellers.
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Methods
Bacterial isolates included in this study
A total of 533 S. Typhi isolates from English cases received by PHE during the period of 1st
April 2014 to 31st March 2017 were included in this study. Ethical approval for the detection of
gastrointestinal bacterial pathogens from faecal specimens, or the identification, characterista-
tion and typing of cultures of gastrointestinal pathogens, submitted to the Gastrointestinal
Bacteria Reference Unit is not required as covered by Public Health England’s surveillance
mandate. Patient travel information was available for 488/533 of the isolates and was obtained
by PHE using an enhanced surveillance questionnaire (https://www.gov.uk/government/
publications/typhoid-and-paratyphoid-enhanced-surveillance-questionnaire), this included
questions pertaining to the destination of any foreign travel that occurred during the likely
incubation period (28 days before onset of symptoms). No specific consent was required from
the patients whose data were used in this analysis because Public Health England has authority
to handle patient data for public health monitoring and infection control under section 251 of
the UK National Health Service Act of 2006. For the remaining 45 isolates, no enhanced sur-
veillance questionnaire was completed or the data collected was incomplete; these were spread
across the four years (n = 15 for 2014, n = 24 for 2015, n = 4 for 2016 and n = 2 for 2017; mean
8.5%). Details of all 533 isolates are provided in S1 Table.
Whole genome sequencing
WGS was conducted as part of routine sequencing of all Salmonella isolates referred to the
Gastrointestinal Bacteria Reference Unit at PHE, as previously described[29]. Briefly, DNA
was fragmented and tagged for multiplexing with NexteraXT DNA Sample Preparation Kits
(Illumina) and sequenced at PHE on a HiSeq 2500 yielding 100 bp paired end reads. FASTQ
data is available from the NCBI Short Read Archive, BioProject accession PRJNA248792. Indi-
vidual accession numbers for isolates analysed in this study are given in S1 Table.
Single nucleotide variant (SNV) analysis and in silico genotyping
Paired end Illumina reads were mapped to the CT18 reference genome (accession AL513382)
[30], which is the standard reference for S. Typhi genomic studies, using RedDog (V1.
beta10.3) available at (https://github.com/katholt/RedDog). Briefly, RedDog maps reads to the
reference genome using Bowtie2 (v.2.2.9)[31], before using SAMtools (v1.3.1)[32] to identify
high quality single nucleotide variant (SNV) calls as previously described[19]. A core SNV
alignment was generated by concatenating alleles with high-quality consensus base calls
(phred score >20), for all SNV sites that had such calls in >95% of genomes (this represents
the 95% ‘soft’ core of the S. Typhi genomes); this alignment was filtered to exclude SNVs in
phage regions and repetitive sequences (354 kb; ~7.4% of bases) in the CT18 reference chro-
mosome as defined previously[10]; S2 Table) and recombinant regions identified by Gubbins
[33]. The resulting alignment of 8053 SNVs was used as input to RAxML (v8.2.8) to infer a
maximum likelihood (ML) phylogeny with a generalised time-reversible model and a Gamma
distribution to model site-specific rate variation (GTR+ Γ substitution model; GTRGAMMA
in RAxML), and 100 bootstrap pseudo-replicates to assess branch support.
Genotypes were inferred for all isolates by screening the Bowtie2 alignment (bam) files for
SNVs used in the extended S. Typhi typing framework, GenoTyphi (code available at https://
github.com/katholt/genotyphi)[11]. GenoTyphi uses 72 specific SNVs to assign isolates to one
of four primary clusters; 16 clades; and 49 subclades[11], with the globally disseminated 4.3.1
(H58) subclade further delineated into lineages I and II (4.3.1.1 and 4.3.1.2).
Informal genomic surveillance of regional distribution of Salmonella Typhi
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In silico characterisation of AMR associated genes and mobile elements
S. Typhi genomes were screened for acquired AMR genes and plasmid replicons using PHE’s
mapping-based Genefinder pipeline as previously described[34], which has been extensively
validated in comparing phenotypic and WGS-derived AMR profiles on ~600 typhoidal Salmo-
nella Typhi and Paratyphi [35]. Reference sequences in Genefinder were curated from those
described in Comprehensive Antimicrobial Resistance Database[36] and PlasmidFinder[37].
Genes were called as present within a genome when detected with 100% coverage and >90%
nucleotide identity to the reference gene. Genefinder was also used to detect point mutations
in the QRDR of chromosomal genes gyrA (codons 83, 87) and parC (codons 79, 80, 84)[35,38].
Isolates were defined as being MDR if genes were detected by Genefinder in the Beta-Lacta-
mases, Trimethoprim, Sulphonamides and Chloramphenicol classes.
ISmapper[39] (v2) was run with default parameters to screen all read sets for insertion sites
of the transposase IS1 (accession X52534) relative to the CT18 reference chromosome
sequence (accession AL513382). The binary data from ISmapper was processed in R using
tidyverse (v1.2.1) (https://cran.r-project.org/package=tidyverse). For six isolates that carried
MDR genes but no plasmid replicon genes, ISMapper was re-run with the minimum read
depth threshold reduced to 1 read (from the default of 6 reads), in order to increase sensitivity
to detect the associated IS1 site. This identified IS1 sites in five of the six isolates (SRR3049053,
SRR5989319, SRR1967049, SRR5500465 and SRR5500455) but not in isolate SRR5500435.
The presence and subtypes of IncHI1 and IncN plasmids was further investigated using plas-
mid MLST (pMLST). Publicly available pMLST schemes for IncHI1[40] and IncN[41], available
at https://pubmlst.org/plasmid/, were used to screen the relevant read sets using SRST2 (v0.1.8)
[42]. The five isolates that were determined to have pST2 versions of the IncHI1 plasmid were
then mapped to the reference sequence of plasmid pAKU1 (accession AM412236) with Red-
Dog, using the same quality control thresholds as described for the chromosomal SNVs. The
coverage level of the plasmid was addressed determining the ratio of average sequencing depth
for the chromosome and the plasmid for all five isolates, with the ratio in the range 0.89–2.29 in
all cases. A pST1 plasmid sequence (pUI1203_01 accession ERR340785) from S. Typhi strain
UI1203 (genotype 3.2.1, isolated from Laos in 2001)[11] was included to provide an outgroup
for tree rooting. The resulting SNV alignment was filtered to exclude non-backbone regions
(66,458 bp) of the pAKU1 plasmid as previously defined [4] of the plasmid, and to exclude SNV
sites present in<95% of plasmid sequences, and recombinant regions detected by Gubbins
(v2.3.2), resulting in a final alignment of 17 SNVs for phylogenetic inference as above.
Genomes with less common AMR profiles were assembled using Unicycler v0.4.6 [43]. The
assemblies were further interrogated for the presence of plasmid replicon genes using ABRi-
cate (https://github.com/tseemann/abricate) and the PlasmidFinder database using a mini-
mum coverage and minimum identity of 90. The location of AMR genes detected, IS1
sequences and IncHI1 plasmid backbone genes was visualised in Bandage v0.8.1 [44].
Trees annotated with MDR, IS1 insertion sites, plasmid replicons and QRDR point muta-
tions were visualised using ggtree v1.8.1[45]. An interactive version of the S. Typhi ML phylog-
eny with associated metadata is found at microreact (https://microreact.org/project/r1njJ_qJ4).
Ciprofloxacin susceptibility phenotyping
The minimum inhibitory concentration (MIC) of ciprofloxacin was measured for 173 isolates
(n = 117 from 2015 and n = 56 from 2016) as part of a previously reported study[35]. Briefly,
MIC was determined by agar dilution using Mueller-Hinton agar, and S. Typhi were inter-
preted as displaying resistance (MIC�0.5 μg/mL) or susceptibility to ciprofloxacin (MIC
<0.06 μg/mL), according to the EUCAST guidelines (v7.1)[35]. For the 173 phenotyped
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isolates, the total number of QRDR mutations per isolate was plotted against the reported
MIC, in R using ggplot2 (v3.0.0)[46].
Results
Countries of travel
A total of 533 S. Typhi isolates were referred from English cases to PHE during the three-year
period between April 2014 and March 2017 (n = 178, n = 176, n = 179 in each year running
from April to March; listed in S1 Table). Of these, 449 cases (84.2%) reported recent foreign
travel (within 28 days of onset of symptoms), spanning 26 countries. A further 39 cases (7.3%)
reported no travel abroad. The proportion of cases reporting no recent travel, which may rep-
resent local transmission within the UK, displayed a non-significant increase from 5.6% in the
first year to 8.9% in the third year (p = 0.5 using Chi-squared trend test). No information on
travel was available for the remaining 45 cases (8.4%). The distribution of travel destinations
for the cases with known travel history are given in Table 1 and Fig 1. The majority of cases
(n = 387, 73%) reported travel to South Asia, particularly India (36%), Pakistan (29%) and
Bangladesh (6%), reflecting travel and migration patterns between England and typhoid
endemic areas. Annual case numbers from India and Bangladesh were constant (mean 64 and
11 per year, respectively; p = 0.2 in each case using Chi-squared trend test), but case numbers
from Pakistan spiked significantly in the third year of the study, to n = 68 (38% of total cases)
compared to n = 45 and n = 43 (25%) in the first two years (p = 0.01 using Chi-squared trend
test). Small numbers of cases reported travel to South East Asia (n = 10, 2%), East Africa
(n = 21, 4%), West Africa (n = 11, 2%) and the Middle East (n = 4, 1%; see Table 1). Five cases
(1%) had reported travel to Europe or North America or South America only.
S. Typhi genotypes by region
The 533 genomes were assigned to 31 unique S. Typhi genotypes using the GenoTyphi scheme
(Fig 2). The majority (n = 391, 73.4%) belonged to subclade 4.3.1 (H58), which was identified
in cases with travel to 14 different countries. Genotype 4.3.1 dominated amongst cases with
reported travel to the South Asian countries associated with the greatest burden of travel-
related cases (India, 79% 4.3.1; Pakistan, 92% 4.3.1; Bangladesh, 52% 4.3.1), and amongst cases
with travel to East Africa (86% 4.3.1; see Table 1). Of the 4.3.1 isolates, 162 (41%) were further
classified to lineage I (4.3.1.1), including 66% of the 4.3.1 isolates from cases with travel to
Pakistan, 94% of those with travel to Bangladesh, and all 4.3.1 isolates from cases with travel to
Mozambique, Tanzania and Zimbabwe (total n = 13). In contrast, lineage II (4.3.1.2)
accounted for 156 (40%) of 4.3.1 genotypes, dominating in returning travellers to India (75%
of 4.3.1 isolates) and accounting for the three 4.3.1 isolates associated with travel to Rwanda
and Uganda (Fig 3). Notably, 4.3.1 was not detected in cases associated with travel to West
Africa (0/11; see Table 1, Fig 3). Other common genotypes include clade 3.3 (6% of total iso-
lates), found in cases with travel to India (9% of all isolates from this location), or Bangladesh
(15%); clade 2.2 (3.1% of total isolates), found in cases with travel to India (2%) or Pakistan
(4.5%); subclade 3.2.2 (2.6% of total isolates), found in 21% of cases with travel to Bangladesh;
and subclade 3.1.1 (1.7% of total isolates), found in 7/11 (63%) of cases with travel to West
Africa, including Nigeria (n = 4/6), Ghana (2/2) and Sierra Leone (1/1).
Multi-drug resistance and QRDR mutations by region
The overall frequency of MDR, defined as carriage of genes associated with resistance to ampi-
cillin (blaTEM), chloramphenicol (catA1) and co-trimoxazole (sul1 or sul2 plus a dfrA gene),
Informal genomic surveillance of regional distribution of Salmonella Typhi
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Table 1. Summary table of S. Typhi collection.
Country Total 4.3.1 (%) MDR (%) Number of QRDR mutations
None (%) One or two (%) Three (%)
South Asia 384 313 (81.5%) 100 (26%) 18 (4.7%) 316 (82.3%) 50 (13%)
Afghanistan 1 1 (100%) 1 (100%) 0 (0%) 1 (100%) 0 (0%)
Bangladesh 33 17 (51.5%) 8 (24.2%) 2 (6.1%) 31 (93.9%) 0 (0%)
India 191 151 (79.1%) 6 (3.1%) 5 (2.6%) 143 (74.9%) 43 (22.5%)
Nepal 3 1 (33.3%) 0 (0%) 1 (33.3%) 1 (33.3%) 1 (33.3%)
Pakistan 156 143 (91.7%) 85 (54.5%) 10 (6.4%) 140 (89.7%) 6 (3.9%)
South East Asia 10 2 (80%) 0 (0%) 7 (70%) 3 (30%) 0 (0%)
Indonesia 3 0 (0%) 0 (0%) 3 (100%) 0 (0%) 0 (0%)
Malaysia 1 1 (100%) 0 (0%) 0 (0%) 1 (100%) 0 (0%)
Myanmar 2 1 (50%) 0 (0%) 0 (0%) 2 (100%) 0 (0%)
Philippines 4 0 (0%) 0 (0%) 4 (100%) 0 (0%) 0 (0%)
Middle East 4 2 (50%) 1 (25%) 2 (50%) 2 (50%) 0 (0%)
Iraq 3 1 (33.3%) 0 (0%) 2 (66.7%) 1 (33.3%) 0 (0%)
UAE 1 1 (100%) 1 (100%) 0 (0%) 1 (100%) 0 (0%)
East Africa 21 18 (85.7%) 11 (52.4%) 12 (57.1%) 9 (42.9%) 0 (0%)
Ethiopia 1 0 (0%) 0 (0%) 1 (100%) 0 (0%) 0 (0%)
Mozambique 1 1 (100%) 1 (100%) 1 (100%) 0 (0%) 0 (0%)
Rwanda 1 1 (100%) 0 (0%) 0 (0%) 1 (100%) 0 (0%)
Tanzania 4 4 (100%) 2 (50%) 2 (50%) 2 (50%) 0 (0%)
Uganda 4 4 (100%) 0 (0%) 0 (0%) 4 (100%) 0 (0%)
Zimbabwe 10 8 (80%) 8 (80%) 8 (80%) 2 (20%) 0 (0%)
West Africa 11 0 (0%) 3 (27.3%) 8 (72.7%) 3 (27.3%) 0 (0%)
Angola 2 0 (0%) 0 (0%) 2 (100%) 0 (0%) 0 (0%)
Ghana 2 0 (0%) 1 (50%) 2 (100%) 0 (0%) 0 (0%)
Nigeria 6 0 (0%) 2 (33.3%) 3 (50%) 3 (50%) 0 (0%)
Sierra Leone 1 0 (0%) 0 (0%) 1 (100%) 0 (0%) 0 (0%)
Central Asia 1 0 (0%) 0 (0%) 0 (0%) 1 (100%) 0 (0%)
China 1 0 (0%) 0 (0%) 0 (0%) 1 (100%) 0 (0%)
North Africa 1 0 (0%) 0 (0%) 0 (0%) 1 (100%) 0 (0%)
Egypt 1 0 (0%) 0 (0%) 0 (0%) 1 (100%) 0 (0%)
Europe 1 0 (0%) 0 (0%) 0 (0%) 1 (100%) 0 (0%)
Greece 1 0 (0%) 0 (0%) 0 (0%) 1 (100%) 0 (0%)
South America 1 0 (0%) 0 (0%) 0 (0%) 1 (100%) 0 (0%)
Peru 1 0 (0%) 0 (0%) 0 (0%) 1 (100%) 0 (0%)
North America 1 0 (0%) 0 (0%) 1 (100%) 0 (0%) 0 (0%)
USA 1 0 (0%) 0 (0%) 1 (100%) 0 (0%) 0 (0%)
No Travel 39 15 (38.5%) 5 (12.8%) 19 (48.7%) 18 (46.2%) 2 (5.1%)
No Travel Information 45 30 (66.7%) 9 (20%) 9 (20%) 32 (71.1%) 4 (8.9%)
Isolates from cases with reported travel to multiple countries not included in table.
UAE: United Arab Emirates
MDR: Multi-drug resistance
QRDR: Quinolone resistance determining region
https://doi.org/10.1371/journal.pntd.0007620.t001
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Fig 1. Summary of S. Typhi received at Public Health between April 2014 to March 2017. a) Map highlighting
countries that were reported as travel destinations for patients from which S. Typhi cultures were collected. Countries
are coloured by major geographical regions. Blank map sourced from https://commons.wikimedia.org/wiki/File:
BlankMap-FlatWorld6.svg b) Number of S. Typhi isolates reporting travel to each country over the three-year period
of study, stratified by date of receipt at PHE.
https://doi.org/10.1371/journal.pntd.0007620.g001
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was 129 (24%). MDR S. Typhi was associated with reported travel to 10 countries from three
main regions, South Asia (26%), East Africa (52%) and West Africa (27%), with high frequen-
cies amongst isolates whose cases report travel to Zimbabwe (8/10, 80%), Nigeria (2/6, 33%),
Tanzania (2/4, 50%), Ghana (1/2, 50%), Bangladesh (8/33, 24%) and Pakistan (85/156, 55%)
(Table 1, Fig 3). MDR was also present at low frequency amongst cases with reported travel to
India (3%), and singleton MDR isolates were detected from Mozambique, United Arab Emir-
ates and Afghanistan. Notably the majority of MDR isolates were linked with travel to Pakistan
(n = 85, 66% of all MDR isolates) and other South Asian countries (n = 100, 78% of all MDR
isolates; see Table 1). No ESBL or carbapenemase genes were detected.
All MDR isolates belonged to either 4.3.1 (n = 125) or 3.1.1 (n = 4, see Fig 2b). The fre-
quency of MDR was highest in 4.3.1.1 (96%), then 3.1.1 (3%), and one isolate in 4.3.1 (Figs 2b
and 3). At the regional level, MDR was common amongst cases associated with travel to East
Africa (52%), West Africa (27%) and South Asia (26%), but not with travel elsewhere (with the
exception of one isolate from UAE; see Table 1). However, there were significant differences
between countries within these regions, associated with differences in the dominant S. Typhi
Fig 2. Membership of S. Typhi by genotypes and association with AMR. a) Population framework tree of the S. Typhi genotypes sequenced at PHE. Background
shading indicates the primary clades. Tree tips indicate individual genotypes assigned by GenoTyphi; tip sizes and colours indicate number of isolates belonging to
each genotype, these values (n) are also printed to the right. b) Frequency of MDR for each genotype (defined based on presence of AMR genes encoding resistance to
the first line drugs ampicillin, trimethoprim-sulfamethoxazole, or chloramphenicol). c) Frequency of QRDR mutations by genotype.
https://doi.org/10.1371/journal.pntd.0007620.g002
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clades (Fig 3). In East Africa and South Asia, MDR was detected amongst cases associated with
travel to the countries dominated by MDR-associated lineage 4.3.1 lineage I (Mozambique,
Tanzania and Zimbabwe in East Africa; and Bangladesh and Pakistan in South Asia; see
Table 1, Fig 3). In West Africa, MDR was detected in three isolates (n = 2 Nigeria, n = 1
Ghana), all belonging to the region’s dominant subclade 3.1.1 (a fourth MDR 3.1.1 infection
had no reported travel).
QRDR mutations were identified in 455 isolates (85.4%) originating from 18 countries
(Table 1, S1 Table). QRDR mutants were most frequent in India (97%), Bangladesh (94%),
Nepal (66%), Pakistan (94%), Myanmar (100%), Uganda (100%), and Nigeria (50%). Singleton
QRDR mutants were also identified in China, Malaysia, Afghanistan, United Arab Emirates,
Egypt, Rwanda, Peru, Greece and Zimbabwe. QRDR triple mutants were identified only in iso-
lates associated with travel to South Asia: 33% of isolates from Nepal, 23% of those from India
and 4% of those from Pakistan (Table 1). Overall, the presence of QRDR mutations was very
common in cases associated with travel to South Asia (95% of all isolates linked to this region),
and significantly less common (p< 2.2e-16 using Chi-squared trend test) in East Africa (43%,)
and West Africa (27%; see Table 1).
Ciprofloxacin MICs have been previously reported for 173 of the S. Typhi isolates (S1
Table)[35], and a comparison of QRDR mutations with these phenotypes is shown in Fig 4 to
facilitate the interpretation of QRDR mutations. These data showed that all isolates carrying a
single QRDR mutation had ciprofloxacin MIC of at least 0.064 μg/mL (exceeding the EUCAST
Fig 3. Geographic distribution of S. Typhi based on reported country of travel. S. Typhi isolates with completed travel questionnaires and reporting travel to only
one country are shown. The number in each circle indicates the total number of cases reporting travel to that country, circle graphs indicate the genotype composition
of the corresponding S. Typhi isolates, stratified by MDR, coloured as per inset legend. Blank map sourced from https://commons.wikimedia.org/wiki/File:BlankMap-
FlatWorld6.svg
https://doi.org/10.1371/journal.pntd.0007620.g003
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threshold for susceptibility); all those with two QRDR mutations had MIC of 0.125 μg/mL;
and all those with three mutations had MIC�1 μg/mL (above the threshold for resistance)
(Fig 4). The most common mutations were gyrA-S83F (n = 271, 51%) and gyrA-S83Y (n = 83,
16%), which were found in 16 genotypes in cases associated with travel to eleven and six coun-
tries respectively (Table 2). Double mutants (gyrA-S38F or -S83Y plus a mutation in parC),
associated with elevation of ciprofloxacin MIC to�0.25 μg/mL (Fig 4), were found in 16
Fig 4. Minimum inhibitory concentration (MIC) for ciprofloxacin versus number of point mutations in QRDRs in two
chromosomal genes. The number of isolates with different combinations of MIC values and point mutations detected in the QRDRs
of two chromosomal genes, gyrA and parC, are shown. The breakpoints of susceptible, reduced susceptibility and resistance are
shown by the background gradient of the plot. The triangle indicates an isolate that carries qnrS-1.
https://doi.org/10.1371/journal.pntd.0007620.g004
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Table 2. Combinations of coding changes detected in the QRDR and their frequency by country of reported travel.
Country Region Gene combination (with amino acid change) Frequency
China Central Asia gyrA-S83F 1
Rwanda East Africa gyrA-S83Y 1
Tanzania gyrA-D87G 2
Uganda gyrA-S83Y 4
Zimbabwe gyrA-D87Y 2
Greece Europe gyrA-S83F 1
Iraq Middle East gyrA-S83F 1
United Arab Emirates gyrA-S83F 1
Egypt North Africa gyrA-D87G 1
Peru South America gyrA-S83F 1
Afghanistan South Asia gyrA-S83F 1
Bangladesh gyrA-S83F 25
gyrA-S83F parC-E84K 2
gyrA-S83Y 1
gyrA-D87N 3
India gyrA-S83F gyrA-D87G parC-S80I 1
gyrA-S83F gyrA-D87N parC-S80I 41
gyrA-S83F 71
gyrA-S83F parC-G78D 2
gyrA-S83F parC-S80I 4
gyrA-S83F parC-E84G 2
gyrA-S83Y 56
gyrA-S83Y parC-Y74X parC-P98X 1
gyrA-S83Y parC-D79G 5
gyrA-D87N 2
gyrA-D87Y 1
Nepal gyrA-S83F gyrA-D87N parC-S80I 1
gyrA-D87G 1
Pakistan gyrA-S83F gyrA-D87N parC-S80I 6
gyrA-S83F 134
gyrA-S83F � 1
gyrA-S83Y 1
gyrA-D87G 2
gyrA-D87N 2
Malaysia South East Asia gyrA-S83F 1
Myanmar gyrA-S83F 1
gyrA-D87N 1
Nigeria West Africa gyrA-S83Y 3
No Travel Information No information gyrA-S83F gyrA-D87N parC-S80I 4
gyrA-S83F 16
gyrA-S83F parC-E84K 1
gyrA-S83Y 9
gyrA-D87G 2
gyrA-D87N 3
gyrA-D87Y 1
(Continued)
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isolates (3.0%) associated with travel to India or Bangladesh. A total of 61 isolates were identi-
fied as QRDR triple mutants, which display resistance to ciprofloxacin (MIC >1 μg/mL, see
Fig 4) and have been associated with fluoroquinolone treatment failure[8]. Most of these
(n = 59) carried gyrA-S83F, gyrA -D87N and parC-S80I mutations, while the remaining two
had a unique profile of gyrA-S83F, gyrA-D87G and parC-S80I and of gyrA-S83FY, parC-Y74X
and parC-P98X (Table 2).
All QRDR double and triple mutants belonged to genotype 4.3.1 and were associated with
travel to South Asia (or no/unknown travel). Overall, QRDR mutations were significantly
more common in 4.3.1 lineage II compared to lineage I (99% vs 91%, p = 0.006, two-sided test
of difference in proportions). The 61 QRDR triple mutants were detected only in S. Typhi
4.3.1 lineage II isolates (Fig 2c) and were associated with either travel to India (n = 43, 22.5%
of all isolates from this location, where lineage II is dominant); travel to neighbouring coun-
tries Pakistan (n = 6) or Nepal (n = 1); travel to multiple destinations including India (n = 5);
no reported travel (n = 2); or no travel information available (n = 4) (Tables 1 and 2). Notably
because all 4.3.1 MDR isolates belonged to lineage I, and all QRDR triple mutants belonged to
lineage II (Fig 2), there were no isolates with both MDR and three QRDR mutations (Fig 2, S1
Table). There were however 119 cases with MDR plus 1–2 QRDR mutations (i.e. reduced sus-
ceptibility to fluoroquinolones, Fig 4). The vast majority of these were 4.3.1 lineage I (n = 115),
most commonly associated with travel to Pakistan (n = 85, 54.4% of isolates from this country),
Bangladesh (n = 8, 24%) and India (n = 6, 3%) but also occasional cases who reported travel to
Zimbabwe (n = 2), Tanzania (n = 2) and United Arab Emirates (n = 1). Three 3.1.1 isolates
were also MDR with one QRDR mutation (n = 2 travel to Nigeria, n = 1 with no recorded
travel).
Plasmid vs chromosomal location of AMR genes in S. Typhi
All MDR isolates belonged to 4.3.1 (n = 125) or 3.1.1 (n = 4) and carried the typical S. Typhi
MDR composite transposon comprising Tn6029 (encoding blaTEM-1, sul2, strAB) inserted in
Tn21 (carrying a class I integron encoding dfrA alleles in the gene cassette and sul1 at the end),
which is in turn inserted within Tn9 (encoding catA1)[47] (see Fig 5a). All 125 MDR 4.3.1 iso-
lates (associated with South Asia and East Africa) carried dfrA7 in the integron cassette and no
plasmid replicons (Fig 5a). In most of these (n = 123, 98%), we detected chromosomal IS1
insertions at sites previously associated with IS1-mediated integration of the MDR composite
transposon (S1 Fig) (cyaA or yidA sites[12,18]). A putative IS1 insertion was detected in the
novel site STY3168 in a single, genome (SRR5500440). Further, of the six isolates with four IS1
sites detected, five had recent travel to Pakistan with last isolate having no reported travel (S1
Fig). Notably, most (93%) of the MDR 4.3.1 isolates also carried a QRDR mutation, the most
Table 2. (Continued)
Country Region Gene combination (with amino acid change) Frequency
No Travel None gyrA-S83F gyrA-D87N parC-S80I 2
gyrA-S83F 15
gyrA-S83Y 3
� The acquired quinolone resistance (qnr) gene, qnrB, was also detected in this isolate. The only other qnr genes detected were two isolates from Zimbabwe that carried
qnrS1 genes but no QRDR mutations.
The three most common point mutations are bolded. Isolates from cases with reported travel to multiple countries not included in table.
https://doi.org/10.1371/journal.pntd.0007620.t002
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common being gyrA-S83F (Table 2, S1 Fig). The four MDR 3.1.1 isolates (associated with
West Africa) carried IncHI1 PST2 plasmids with dfrA15 in the integron cassette (Fig 5b). An
IncHI1 PST2 plasmid was also identified in a single non-MDR 2.3.1 isolate associated with
travel to Nigeria. The plasmid backbone was very closely related to that of the 3.1.1 West Afri-
can plasmids but carried dfrA1 in the integron cassette and lacked the chloramphenicol and
ampicillin resistance genes catA1 and blaTEM (Fig 5a and 5b).
Plasmid replicon and AMR gene screening identified additional plasmid replicons and
AMR genes at low frequency. Two of the MDR 4.3.1.1 isolates from Zimbabwe carried IncN
(subtype PST3) plasmids. In addition to the genes typical of the MDR composite transposon
(with dfrA7 in the integron), these isolates also carried qnrS, dfrA14 and tet(A). It was not pos-
sible to resolve the precise locations of the acquired AMR genes due to the limitations of short
read assembly. As these isolates lack QRDR mutations, the presence of the qnrS gene is pre-
dicted to confer reduced susceptibility to fluoroquinolones but not full resistance; indeed, one
of the isolates (SRR4063811) was phenotyped and displayed reduced susceptibility to cipro-
floxacin, with MIC 0.25 μg/mL. IncN plasmids (subtype PST5) were found in three non-MDR
4.3.1.2 isolates that carried dfrA15, sul1 and tet(A). These isolates (two from India, one with no
Fig 5. Mobilisation of MDR element in S. Typhi. a) Structure of the MDR composite transposon in S. Typhi strain ERL12960 (4.3.1 lineage I) is shown (accession
ERL12960). MDR genes are those encoding resistance to the first line drugs ampicillin, trimethoprim-sulfamethoxazole or chloramphenicol b) Phylogeny showing
genetic relationships between the five IncHI1 PST2 S. Typhi isolates identified in this study, based on SNVs identified in the plasmid backbone sequence and rooted
using the PST1 plasmid pUI1203_01 (accession ERR340785) as an outgroup. The presence of AMR genes detected in each genome is indicated in the heatmap, with
alleles specified for dfrA and blaTEM genes.
https://doi.org/10.1371/journal.pntd.0007620.g005
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reported travel) were also QRDR triple mutants and thus predicted to be fully resistant to fluo-
roquinolones. The combination of dfrA14, sul2, blaTEM-1, strA and strB was detected in three
4.3.1.1 isolates with no QRDR mutations (two with travel to Tanzania, one with no travel
information). All three carried sequences with similarity (100% nucleotide identity and 50%
coverage) to a FIBK plasmid carrying dfrA14, sul2 and blaTEM-1 that was previously sequenced
from a 2008 Tanzanian S. Typhi, strain 129–0238 (GenBank accession LT904889)[12]. The
same combination of AMR genes (dfrA14, sul2, blaTEM-1, strA and strB) plus tet(A) were also
found in a 3.1.1 gyrA-S83Y isolate from Nigeria that harboured an IncY plasmid replicon.
Discussion
Here we demonstrate the utility of using S. Typhi WGS data generated routinely at a public
health laboratory in the UK to serve as informal surveillance for different geographical regions
where typhoid fever is endemic. The PHE dataset encompasses a diverse collection of 533 S.
Typhi isolates from multiple geographical regions collected over a three-year sampling period
(Fig 1). As typhoid fever has not been endemic in England since the successful interventions of
the major controlling measures, water sanitation and hygiene complemented with antimicro-
bial therapy[27,48], it is assumed that notified cases to PHE are associated with returned trav-
ellers and their contacts. The collection is biased towards isolates from South Asia and East
Africa which reflects historical and contemporary ties between England and these regions,
however these are also regions that experience a high burden of typhoid fever and could bene-
fit from the AMR and WGS data obtained routinely by PHE. Notably, public health agencies
in other countries receive S. Typhi isolates reflecting the distinct travel habits of their own pop-
ulations (for example Institut Pasteur receives more S. Typhi from travellers visiting Franco-
phone countries in Africa and former French colonies such as Vietnam), and the synthesis of
these diverse collections could potentially provide more extensive sentinel surveillance cover-
age of typhoid endemic regions.
Typing the S. Typhi isolates using the GenoTyphi scheme enabled rapid classification of the
533 genomes into 31 distinct lineages (Fig 2). This simple tree-free approach showed clustering
of subclades by geographical region of travel that was consistent with previous previously
reported geographical patterns[11], providing support for the use of travel associated isolates
as an indicator of local pathogen populations. Notable examples include the detection of MDR
subclade 4.3.1 in East Africa and South Asia [8,15], and the complete absence of subclade 4.3.1
in the isolates from West Africa[14] (Fig 3). Genomes from cases reporting travel to West
Africa were genotyped as 3.1.1, consistent with earlier studies where 3.1.1 was found to be the
main S. Typhi lineage in the region[13,14]. Furthermore, for isolates with travel to more than
one country, the genotype can help to discern the most likely origin of the infection; for exam-
ple, for one case reporting travel to Nigeria and Turkey, the genome isolate (SRR558502) was
identified as genotype 3.1.1, suggesting that the pathogen was most likely acquired in Nigeria.
This further demonstrates the public health utility of WGS data on returning traveller isolates.
Notably the GenoTyphi scheme provides a mechanism and nomenclature for such insights to
be achieved simply and rapidly from individual genomes and by different laboratories working
independently, without need for phylogenetic tree construction or other comparative analyses.
Data from this study revealed that reduced susceptibility to fluoroquinolones was common
amongst S. Typhi associated with diverse geographic sites and genotypes. However, the cipro-
floxacin resistant QRDR triple mutants were all from cases belonging to subclade 4.3.1.2 (Fig
2, Table 2), the majority of which had reported travel to South Asia, mainly India. None of
these QRDR triple mutants were also MDR, which was associated with cases belonging to sub-
clade 4.3.1.1. This is in line with previous observations, and others have speculated there may
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be a fitness cost to the carriage of QRDR triple mutants particularly in the MDR background
[19]. These data align with previous findings[8,19], and support the hypothesis that high levels
of fluoroquinolone exposure in India through healthcare and the environment are driving the
emergence of resistant S. Typhi and other pathogens in the region[49] and contributing to
treatment failure for typhoid fever[8]. Further, in addition to confirming that QRDR triple
mutants are resistant to ciprofloxacin, the MIC data clearly showed that even a single QRDR
mutation is associated with reduced ciprofloxacin susceptibility (MIC 0.06–0.25 μg/mL) (Fig
4), which has also been associated with clinical failure[35,50]. Single QRDR mutations are not
associated with a fitness cost[51], and are present in MDR isolates, suggesting that this may
further limit treatment options. While phenotypic MICs are still advised for clinical treatment,
inferring susceptibility to antimicrobials from WGS data is appropriate for surveillance pur-
poses [35].
Strikingly in this data set all 4.3.1 MDR isolates carried the composite transposon integrated
in the chromosome, suggesting an enormous shift in the burden of MDR typhoid from plas-
mid-borne resistance. This is of grave concern as it means that there is likely to be very little fit-
ness cost associated with carriage of the MDR transposon. In the late 1990s the increase in
MDR typhoid in Asia prompted a switch to fluoroquinolones for treatment, which in Nepal
and other regions was followed by almost complete loss of the MDR plasmid from the S. Typhi
population, suggesting that the fitness cost of the plasmid leads to plasmid loss in the absence
of selection from the first-line drugs. However, the integration of the MDR transposon into
the S. Typhi chromosome likely alleviates any fitness cost, making it more likely that MDR will
be maintained even in the absence of selection for the specific resistances encoded.
A key limitation of our MDR element analysis is that the routine genomic surveillance data
generated at PHE is restricted to short-read Illumina sequences, which prohibited the full reso-
lution of complex MDR loci and their precise locations in the S. Typhi genome. Nevertheless,
using short-read mapping approaches, we were able to confirm that in nearly all MDR isolates
the MDR loci could be localised to plasmids or chromosomal integration sites that have been
previously fully resolved in S. Typhi using long reads [52,18]. Notably, 98% of plasmid-free
MDR isolates showed evidence of chromosomal integration of the MDR element at the known
sites yidA or upstream of cyaA in the 4.3.1.1 lineage. The other MDR isolates may harbour the
MDR transposon in novel genetic contexts, which could potentially be resolved using long-
read sequencing. PHE has demonstrated the utility of this approach previously, including in S.
Typhi [28], but does not currently conduct long-read sequencing as a routine part of Salmo-
nella genomic surveillance.
Of particular note was the increase in number of IS1 insertions in from cases in subclade
4.3.1.1 with reported travel to Pakistan (S1 Fig). We may hypothesise that the S. Typhi from
this region may be more likely to acquire novel mechanisms in response to local selective pres-
sures. Indeed, the recent acquisition of an IncY plasmid harbouring blaCTX-M-15 and qnrS
genes has resulted in the emergence of an XDR lineage of S. Typhi from Pakistan[24] and an
IncI1 plasmid encoding blaCTX-M-15 in an S. Typhi from Bangladesh[52] provides evidence for
this hypothesis, highlighting the importance of ongoing surveillance of these regions that expe-
rience a high burden of typhoid fever.
Currently there are three critical AMR threats posed by S. Typhi, namely the dissemination
of mobile AMR genes mediating MDR profiles, the evolution of point mutations in gyrA and
parC, two core housekeeping genes, that confer differing levels of fluoroquinolone resistance
(Figs 2 and 4), and the recent emergence of XDR S. Typhi. The WGS data presented here pro-
vide insight into changing AMR dynamics within S. Typhi. Importantly, the concordance of
genomic and phenotypic AMR data for ciprofloxacin resistance in this study (Fig 4) which
have been extensively characterised for S. Typhi for multiple drugs previously[35],
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demonstrates the utility of WGS for robustly characterising AMR profiles. Here, two of the
AMR threats where characterised within the S. Typhi collection, reflecting geographical differ-
ences in AMR profiles. While no XDR S. Typhi had been detected in the PHE collection
between April 2014 and March 2017, the first XDR S. Typhi isolate in a returned traveller with
recent travel to Pakistan shortly after XDR S. Typhi were reported from Pakistan has been
identified[24,28]. This highlights the value in using these data as informal surveillance of S.
Typhi as we hypothesise that resistance to second-line drugs such as azithromycin will arise
under continued selective pressure as has occurred with previous drugs.
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